Genmab — December 2020
-
God morgen.
-
Ok..hvor meget drejer det sig om for Genmab?
-
Nyheden var allerede ude I går. Se 14:08. Genmab får 6% royalties på Tepezza
-
Genmab skal vel ikke komme med noget, hvis det ikke medfører nedjustering...
-
Så vi taler om 12 dages manglende salg i 2020. Det er peanuts for 2020
-
Hvis Tepezza ikke kan sælges i hele 2021 (næppe sandsynligt), kan det betyde ca. 60 millioner $ i tabte royalties
-
Mon ikke det blot er en lagerforskydning i første omgang. Min umiddelbare tanke er, at det ikke er dag til dag levering, så effekten må da være minimal og nærmest ikke eksisterende
(?) -
Bortset fra det, så er overskriften på Børsens artikel i går rent clickbait.
-
"the PD-L1x4-1BB dual body [] has broad potential in a range of solid tumors, including those where checkpoint therapy is currently established but also more difficult tumors where first-generation checkpoint inhibitors have not been as successful. This bispecific antibody has outperformed conventional checkpoint inhibitors in preclinical animal models. We have seen strong evidence in the preclinical setting of its ability to amplify the effect of our vaccines as well."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind